HIGHLIGHTS
SUMMARY
Unfortunately, partial patients with wild-type EGFR NSCLC could not benefit from the initial treatment with icotinib, and other patients with EGFR mutant NSCLC only received short-term clinical benefits from icotinib treatment, indicating that innate and acquired resistance limit broad application and long-term efficacy of icotinib. Based on the above observations, the authors demonstrated the responses of EGFR-mutated NSCLC cells to icotinib, and explored the biological functions and action mechanisms of autophagy in icotinib-resistant cells in_vitro and in_vivo. To explore the impacts of CQ on resistance to icotinib in_vivo, the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.